Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2023-173991

Published: 2023

Journal Articles

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Blood (2023) 141 (10): 1159–1168.

https://doi.org/10.1182/blood.2022016862

Published: 2023

Includes: Supplemental data

Journal Articles

A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01

Francine M. Foss, Pierluigi Porcu, Steven M. Horwitz, Koji Izutsu, Kenji Ishitsuka, Kazunobu Kato, Jin Jin, Yining Du, Ai Inoue

Blood (2021) 138 (Supplement 1): 2533.

https://doi.org/10.1182/blood-2021-144676

Published: 2021

Journal Articles

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Blood (2021) 138 (Supplement 1): 303.

https://doi.org/10.1182/blood-2021-146657

Published: 2021

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Stephen M. Ansell, Craig H. Moskowitz, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, Ranjana H. Advani

Blood (2018) 131 (11): 1183–1194.

https://doi.org/10.1182/blood-2017-10-811224

Published: 2018

Includes: Supplemental data

Journal Articles

Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M Vose, MD, Radhakrishnan Ramchandren, MD, Tatyana A Feldman, MD, Ann S LaCasce, MD MSc, Stephen M Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, MD, Ranjana H. Advani, MD

Blood (2017) 130 (Supplement 1): 649.

https://doi.org/10.1182/blood.V130.Suppl_1.649.649

Published: 2017

Journal Articles

Chromosome 9p24.1/ PD-L1 / PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Blood (2016) 128 (22): 2923.

https://doi.org/10.1182/blood.V128.22.2923.2923

Published: 2016

Journal Articles

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Ishan Hirji, Kim Cocks, Jeffrey McDonald, Erin Mann, Kazunobu Kato, MD, David Cella, PhD

Blood (2016) 128 (22): 1831.

https://doi.org/10.1182/blood.V128.22.1831.1831

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F Herrera, MD, Nancy L Bartlett, MD, Radhakrishnan Ramchandren, MD, Julie M Vose, MD, Alison J Moskowitz, MD, Tatyana A Feldman, MD, Ann S LaCasce, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Kazunobu Kato, MD, Abraham Fong, MD PhD, Ranjana H Advani, MD

Blood (2016) 128 (22): 1105.

https://doi.org/10.1182/blood.V128.22.1105.1105

Published: 2016

Journal Articles

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

John M. Timmerman, MD, Andreas Engert, MD, Anas Younes, MD, Armando Santoro, Philippe Armand, MD PhD, Michelle A Fanale, MD, Graham P. Collins, MD PhD, Voravit Ratanatharathorn, MD, John Kuruvilla, MD, Jonathon B. Cohen, MD, Kerry J Savage, MD, Marek Trneny, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Scott J Rodig, Kazunobu Kato, MD, Anne Sumbul, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 1110.

https://doi.org/10.1182/blood.V128.22.1110.1110

Published: 2016

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD

Blood (2016) 128 (22): 3502.

https://doi.org/10.1182/blood.V128.22.3502.3502

Published: 2016

Journal Articles

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Christopher Bredeson, Jennifer LeRademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie R. Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, Elizabeth Armstrong, Angela Smith, J. Douglas Rizzo, Jeanne M. Burkart, Marcelo C. Pasquini

Blood (2013) 122 (24): 3871–3878.

https://doi.org/10.1182/blood-2013-08-519009

Published: 2013

Includes: Supplemental data

Journal Articles

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Blood (2013) 122 (21): 768.

https://doi.org/10.1182/blood.V122.21.768.768

Published: 2013

Journal Articles

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Blood (2012) 120 (21): 3080.

https://doi.org/10.1182/blood.V120.21.3080.3080

Published: 2012

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Cesar O. Freytes, MD, Juan J. Toro, MD, MSci, Rosa F. Yeh, PharmD, Edward A. Stadtmauer, MD, Voravit Ratanatharathorn, MD, Gorgun Akpek, MD, MHS, Entezam Sahovic, MD, Guido J. Tricot, MD, PhD, Paul J. Shaughnessy, MD, Darrell J. White, MD, Tulio E. Rodriguez, MD, Scott R. Solomon, MD, Louie H. Yu, BS, Shiva Patil, PhD, Yiping Sun, PhD, Elizabeth Armstrong, MS, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 4509.

https://doi.org/10.1182/blood.V118.21.4509.4509

Published: 2011

Journal Articles

Influence of Multimer Size and a Natural Dimorphism on the Activity of Convulxin.

Kazunobu Kato, M.D., Ph.D., Yann Cheli, Kenichi Furihata, M.D., Ph.D., Gandhi Radis-Baptista, Ph.D., Thomas J. Kunicki, Ph.D.

Blood (2004) 104 (11): 3927.

https://doi.org/10.1182/blood.V104.11.3927.3927

Published: 2004

Journal Articles

Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size

Kazunobu Kato, Constantino Martinez, Susan Russell, Paquita Nurden, Alan Nurden, Steven Fiering, Jerry Ware

Blood (2004) 104 (8): 2339–2344.

https://doi.org/10.1182/blood-2004-03-1127

Published: 2004

NARROW

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Chromosome 9p24.1/ PD-L1 / PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Influence of Multimer Size and a Natural Dimorphism on the Activity of Convulxin.

Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only